Cardiac Insight
Cardiac Insight is a Bellevue, WA-based privately held medical device company that develops and sells the Cardea SOLO 7-day wearable ECG sensor and the Cardea 20/20 12-lead athlete-screening ECG system to healthcare providers, sports organizations, and academic researchers, and is a subsidiary of Korea's DreamTech.
- Company typePrivate
- Founded2013
- HeadquartersBellevue, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cardiac Insight does
Cardiac Insight, Inc. is a privately held medical device company headquartered in Bellevue, Washington, founded in 2013 by Dr. David Hadley and Dr. Victor Froelicher. The company develops and sells two core ECG diagnostic products: Cardea SOLO, a 23-gram water-resistant single-use wearable ambulatory sensor that continuously records up to one million heartbeats over seven days and pairs with a Windows-based analysis software that produces draft diagnostic reports in under five minutes; and Cardea 20/20, a handheld 12-lead ECG system that embeds the International Consensus Criteria for athlete screening and reports an industry-low ~2% false positive rate (vs. a ~30% industry norm). Cardiac Insight serves three distinct customer segments — healthcare providers and cardiology practices (primary), sports organizations and athletic programs (primary, including MLB's LA Dodgers and MLS's LA Galaxy), and academic/pharmaceutical researchers — through a direct sales motion supported by phone, a Sales Hub portal, and event-driven community partnerships.
Cardiac Insight generates revenue primarily through capital hardware sales of the Cardea 20/20 device and recurring unit sales of single-use Cardea SOLO sensors, supplemented by software licensing for the SOLO analysis platform. Providers retain full Category I CPT reimbursement for long-term ECG monitoring because the in-office software eliminates third-party IDTF data transfer. The company is a subsidiary of DreamTech, a KOSPI-listed Korean electronic components manufacturer that acquired Cardiac Insight in 2022 and whose CEO Min Kim also serves as Cardiac Insight's CEO. Following the acquisition, the company has expanded its leadership bench (COO, CSO, CMO, President/CGO) and is scaling commercial operations, supported by community screening partnerships with Who We Play For, Vegas Has a Heart, and Parent Heart Watch, and a research sales channel offering flexible, contract-free ordering for academic and pharmaceutical users.
Cardiac Insight firmographics
Firmographics- Name
- Cardiac Insight
- Legal name
- Cardiac Insight, Inc.
- Website
- https://cardiacinsightinc.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cardiac Insight is a Bellevue, WA-based privately held medical device company that develops and sells the Cardea SOLO 7-day wearable ECG sensor and the Cardea 20/20 12-lead athlete-screening ECG system to healthcare providers, sports organizations, and academic researchers, and is a subsidiary of Korea's DreamTech.
- Ownership category
- akta.pro rank
Cardiac Insight industry classification
Industry- Product category
- Cardiac Diagnostic Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)
- akta.pro secondary industries
- Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Consumer Health Wearables & Fitness Trackers (Wellness Monitoring) (HLAHACAJ)
Keywords
Where Cardiac Insight is headquartered
LocationHeadquarters
- HQ city
- Bellevue
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cardiac Insight business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- ECG Device Sales: Cardiac Insight generates revenue through the sale of its ECG monitoring devices including the Cardea SOLO wearable sensor and Cardea 20/20 12-lead ECG system. These are capital medical device purchases by healthcare providers and sports organizations.
- Software Licensing: The company sells licenses for its proprietary Cardea SOLO analysis software which installs on Windows PCs. Software generates diagnostic reports and provides clinical tools for ECG interpretation.
- Healthcare Reimbursement: Providers using Cardea SOLO receive reimbursement through Category I CPT codes for long-term ECG monitoring. The company supports global billing allowing providers to retain full reimbursement without sharing with IDTF centers. Reimbursement rates have increased, making it cost-effective for providers.
- Research & Academic Sales: Cardea SOLO is offered to academic institutions, pharmaceutical companies, and industry researchers for ECG data collection in clinical studies, with flexible ordering without long-term contracts.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Cardea SOLO ECG System - Healthcare Provider Pricing |
| Unit Pricing | Pay-as-you-go | Cardea SOLO for Research - Flexible Ordering |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
Cardiac Insight product offering
Product offeringCore offering
Cardiac Insight designs, manufactures, and sells wearable and handheld ECG diagnostic devices and proprietary analysis software for cardiac monitoring and screening. Its flagship products are the Cardea SOLO 7-day wearable ambulatory ECG sensor with companion Windows analysis software, and the Cardea 20/20 handheld 12-lead ECG system purpose-built for athlete cardiac screening. The company sells primarily to healthcare providers, sports organizations, and academic research institutions.
Product overview
Cardiac Insight offers two core ECG diagnostic products: Cardea SOLO and Cardea 20/20. Cardea SOLO is a 7-day wearable ambulatory ECG monitoring system for detecting arrhythmias in general patients, comprising a disposable sensor, smart cable, and proprietary analysis software. Cardea 20/20 is a handheld 12-lead ECG device specifically designed for athlete cardiac screening using International Consensus Criteria. Both products feature proprietary automated analysis algorithms, though they serve different clinical use cases—continuous long-term monitoring for Cardea SOLO versus point-of-care 12-lead screening for Cardea 20/20.
Differentiator
Problem solved
Functional benefit
Brands
- Cardea SOLO: A 7-day wearable ambulatory ECG sensor with software-assisted ECG analysis for detecting cardiac arrhythmias.
- Cardea 20/20
Products and services
- Cardea SOLO ECG System A wearable ambulatory ECG monitoring system consisting of a lightweight 23g water-resistant sensor worn for up to 7 days, a smart USB cable, and proprietary analysis software that generates diagnostic reports in under 5 minutes with over 96% positive predictive value for arrhythmia detection. Designed for healthcare providers to conduct continuous cardiac monitoring for arrhythmia detection, atrial fibrillation diagnosis, and cardiac event monitoring in patient populations.
- Cardea 20/20 ECG System A handheld 12-lead ECG diagnostic system designed specifically for athlete cardiac screening, featuring automated interpretation algorithms with the lowest false positive rate in the industry (~2%) using International Consensus Criteria, 16-second recording duration, and USB connectivity to Windows PCs. Built for sports medicine physicians, athletic programs, and sports organizations conducting pre-participation athlete screening and sudden cardiac arrest prevention.
Quantifiable outcome
- False positive rate reduced to ~2% compared to industry norm of 30%
- +5 more outcomes
Companies that use Cardiac Insight
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
Cardiac Insight technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability3 records
Feature5 records
Cardiac Insight partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered major, significant and minor.
- Parent Heart WatchmajorCardiac Insight supported Parent Heart Watch's second annual National Youth Heart Screening Day, providing free ECG screenings to over 2,400 children and young adults across 14 states. The event identified 53 youth at risk for sudden cardiac arrest and included emergency response training.
- Who We Play FormajorWho We Play For is a nonprofit organization focused on preventing sudden cardiac arrest in young athletes. Cardiac Insight serves as the official ECG provider for Who We Play For's screening events, powering free heart screenings across schools and communities.
- Vegas Has a HeartsignificantVegas Has a Heart is a nonprofit collaborating with Cardiac Insight to screen student athletes for cardiac issues. The organization has partnered with notable figures including Shaq (Shaquille O'Neal) and Gatorade Player of the Year Xavion Stanton to raise awareness for sudden cardiac arrest prevention.
- LA DodgerssignificantMLB's Los Angeles Dodgers partnered with Cardiac Insight for athlete heart screening initiatives. Players including Joe Kelly, Tony Gonsolin, and Matt McLain have supported the #CheckYourHeart national movement to raise awareness for youth heart screenings.
- LA GalaxyminorMLS team LA Galaxy partnered with Cardiac Insight for athlete cardiac screening using Cardea 20/20 ECG technology.
- Liquid Packaging SolutionsminorLiquid Packaging Solutions supported the National Youth Heart Screening Day event alongside Cardiac Insight and Parent Heart Watch.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Cardiac Insight competitors and assessment
Company assessmentDirect peers
- iRhythm Technologies: iRhythm's Zio XT and Zio AT are the leading ambulatory ECG patch monitors in the US market and the primary direct competitor to Cardea SOLO. Both companies serve healthcare providers needing 7-14 day continuous cardiac monitoring with automated arrhythmia detection.
- Bardy Diagnostics (BardyDX): BardyDX's CAM Patch is a direct competitor in ambulatory ECG monitoring, with a similar single-use patch design and up to 14-day wear period. BardyDX was acquired by Hillrom, providing distribution scale through Baxter's clinical channels.
- Preventice Solutions: Preventice developed the BodyGuardian MINI family of remote cardiac monitors, a direct competitor to Cardea SOLO in ambulatory ECG monitoring. Now part of Boston Scientific, it competes across diagnostic, monitoring, and connected health workflows.
Broad incumbents
- Philips: Philips' ePatch ambulatory ECG monitor directly competes with Cardea SOLO in the extended cardiac monitoring space. As a global medtech incumbent, Philips has broader product portfolio, larger distribution, and deeper hospital relationships than Cardiac Insight.
- Boston Scientific: Boston Scientific's BodyGuardian MINI (acquired via Preventice Solutions) is a direct ambulatory ECG competitor to Cardea SOLO. Boston Scientific brings significantly larger R&D, sales, and regulatory resources to the cardiac monitoring category.
- GE HealthCare: GE HealthCare offers a broad portfolio of cardiac diagnostic and monitoring solutions including ECG systems, patient monitors, and ambulatory devices. While not a direct competitor in the ambulatory patch niche, it competes for the same cardiology budgets and hospital relationships.
- Medtronic: Medtronic has a broad cardiac diagnostics and monitoring portfolio including insertable cardiac monitors (Reveal LINQ) and remote monitoring infrastructure that competes with Cardiac Insight in arrhythmia detection, though it primarily addresses the implantable rather than wearable ambulatory segment.
Emerging players
- AliveCor: AliveCor's KardiaMobile devices offer single-lead ECG recording for both consumer and clinical use, overlapping with Cardiac Insight's arrhythmia detection focus but emphasizing shorter-duration, consumer-friendly form factors versus 7-day ambulatory wear.
- Eko Health: Eko Health combines digital stethoscopes with AI-powered ECG and cardiac disease detection, overlapping with Cardiac Insight's diagnostic screening use cases — particularly in primary care and athlete screening workflows. Emerging player with growing clinical adoption.
Others
- Apple: Apple Watch ECG functionality represents an indirect consumer-grade competitor for cardiac rhythm monitoring and arrhythmia detection. While not a clinical-grade substitute, Apple Watch ECG normalizes self-monitoring behavior and could either expand the market or commoditize low-acuity arrhythmia screening.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Cardiac Insight social profiles
Digital presenceCardiac Insight financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cardiac Insight leadership team
Management profileNumber of profiles
Profiles7 records
Cardiac Insight funding detail
Funding detailFunding overview
Funding rounds12 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cardiac Insight M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cardiac Insight
What does Cardiac Insight do?
Cardiac Insight designs, manufactures, and sells wearable and handheld ECG diagnostic devices and proprietary analysis software for cardiac monitoring and screening. Its flagship products are the Cardea SOLO 7-day wearable ambulatory ECG sensor with companion Windows analysis software, and the Cardea 20/20 handheld 12-lead ECG system purpose-built for athlete cardiac screening. The company sells primarily to healthcare providers, sports organizations, and academic research institutions.
Is Cardiac Insight a public or private company?
Cardiac Insight is a private company. It is classified as corporate owned and is currently operating.
When was Cardiac Insight founded?
Cardiac Insight was founded in 2013. It employs 11 to 50 people.
Where is Cardiac Insight based?
Cardiac Insight is headquartered in Bellevue, United States, in the North America region.
How does Cardiac Insight make money?
Four revenue lines are on record. ECG Device Sales are the primary driver. The others are software Licensing, healthcare Reimbursement and research & Academic Sales.
Who are Cardiac Insight's main competitors?
Direct peers on record are iRhythm Technologies, Bardy Diagnostics (BardyDX) and Preventice Solutions. Broad incumbents are Philips, Boston Scientific, GE HealthCare and Medtronic. Emerging players are AliveCor and Eko Health. Apple is listed as an others.
Does Cardiac Insight have an API?
No public API is recorded for Cardiac Insight.
What industry is Cardiac Insight in?
Cardiac Insight's product category is Cardiac Diagnostic Devices. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3845.